ArticleFrontiers in medicine2025
Assessing cross-national inequalities and predictive trends in gout burden: a global perspective (1990-2021).
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Effect of Hyperuricemia on Cognitive Impairment: A Cohort Study and Systematic Review.Nutrients · 2026Pooled it
- A machine learning approach to metabolomics identifies putative biomarker candidates and dysregulated pathways for distinguishing gout from asymptomatic hyperuricemia in the Zhuang population.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Traditional Chinese Medicine in Hyperuricemia: Current Advances, Mechanistic Insights, and Clinical Challenges.International journal of general medicine · 2026Review
- Global burden of gout attributable to high BMI (1990-2021) and causal link with obesity: a GBD and Mendelian randomization study.Therapeutic advances in endocrinology and metabolism · 2026Article
- Mitochondrial Oxidative Stress and Vascular Remodeling in Uric Acid Nephropathy: Mechanistic Insights and Therapeutic Implications.International journal of nephrology and renovascular disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gout, caused by hyperuricemia and the deposition of monosodium urate crystals in joints, remains a major global health issue. Despite progress in treatment, its prevalence continues to rise, contributing to comorbidities like cardiovascular and chronic kidney diseases. Understanding global trends and sociodemographic disparities is crucial for developing targeted interventions. Methods: We analyzed gout prevalence, incidence, and disability-adjusted life years (DALYs) from 1990 to 2021, stratified by age, sex, and economic development. Decomposition analysis quantified the impact of demographic factors, while advanced analysis assessed the relationship between gout burden and socioeconomic development. Prediction models forecasted future trends, and cross-national inequalities were evaluated to highlight disparities across regions with different development levels. Results: Between 1990 and 2021, the global prevalence of gout increased from 22,264,515 (95% UI: 17,793,190-27,965,605) to 56,474,572 (95% UI: 45,161,987-70,288,316), with the age-standardized prevalence rate (ASPR) rising from 536.54 to 653.82 per 100,000 population [(Estimated annual percentage changes) EAPC: 0.87%, 95% CI: 0.80-0.95]. The incidence of gout cases increased by 136.1%, with the age-standardized incidence rate (ASIR) rising by 17.12% over this period. Similarly, the age-standardized death rate (ASDR) grew by 21.30%, accompanied by a substantial increase in DALYs. Decomposition analysis revealed that aging significantly contributed to increased gout prevalence in Middle SDI regions (36.79%), while population growth was the dominant factor in Low SDI regions (98.58%). Advanced analysis indicated substantial gaps between observed gout burden and optimal levels in high-SDI countries, such as the United States and Australia, highlighting unrealized opportunities for improving outcomes. Prediction analysis projected a stable global burden of gout from 2021 to 2045, with notable gender-specific and age-specific trends. Cross-national inequality analysis showed worsening disparities in gout prevalence, incidence, and DALYs between high- and low-SDI regions, reflected in increasing Slope Index of Inequality and Health Concentration Index values from 1990 to 2021. Conclusion: The global burden of gout has risen, with high-SDI regions facing risks from lifestyle changes and obesity, while low-SDI regions struggle with healthcare access. Public health strategies should focus on modifiable risk factors, healthcare infrastructure, and gender- and age-specific trends to address disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.